ITF Pharma, the US subsidiary of privately-held European specialty pharma Italfarmaco SPA, is gearing up to roll out Tiglutik – an easy-to-swallow liquid formulation of the mainstay amyotrophic lateral sclerosis (ALS) therapy riluzole – in mid-October in the US, following approval on Sept. 5.
The US FDA approved ITF Pharma's oral suspension formulation of riluzole – a treatment given twice daily using an oral syringe – for ALS, also known as Lou Gehrig's disease
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?